We then used MEK inhibitor Trametinib to examine its inhibitory effect on Osimertinib-resistant NSCLC cells (P_AZDR1 and H1975+CAF_R1) and found it restored Osimertinib sensitivity remarkably (Figure 3A). The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.